Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Secondary Issues

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Feb 24, 2021 8:40am

180 Views

Post# 32645085

RE:RE:RE:RE:RE:Secondary Issues

The raise to have full PH3 funding for partner discussions / having strength makes sense The warrants as part is bush league (not thinking big enough)... if Antibe is truly undervalued then any buyer will be incentivized to buy at a market discount or place the warrant price at $15 and give a higher ceiling for exercise as right now we now have another floor of warrants that will be sold as the pps eventually starts to rise...Dan and team IMO proved they are not thinking big enough imo...

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario